直接口服抗凝药在外周动脉疾病患者中的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析共纳入10项研究,其中4项研究纳入14,257例外周动脉疾病患者,比较阿司匹林±氯吡格雷与DOAC±抗血小板药。结果显示非DOAC使用者再干预率更高(RR 1.12;95%CI 1.01-1.24;P=0.025),两组大出血、全因死亡和心血管死亡无统计学差异。
要点
- DOAC单用或联合抗血小板药与更低再干预率相关(RR 1.12;95%CI 1.01-1.24;P=0.025)。
- DOAC使用者与非使用者大出血风险无统计学差异(RR 0.78;95%CI 0.50-1.23;P=0.285)。
- 全因死亡和心血管死亡在两组间无统计学差异。
核心结论
- DOAC单用或联合抗血小板药可能与更低再干预率相关,且不增加不良出血事件风险。
- 研究未检测到DOAC使用者与非使用者在全因死亡、MACEs和MALEs方面的差异。
研究设计与样本
- 系统综述与荟萃分析,按照PRISMA指南执行,使用随机效应模型计算风险比(RR)。
- 共纳入10项研究;其中4项研究纳入14,257例PAD患者,比较ASA±氯吡格雷(N=5,894)与DOAC±抗血小板药(n=8,363)。
主要发现
- 非DOAC使用者再干预率显著高于DOAC使用者(RR 1.12;95%CI 1.01-1.24;P=0.025)。
- 两组大出血无统计学差异(RR 0.78;95%CI 0.50-1.23;P=0.285)。
- 两组全因死亡无统计学差异(RR 0.98;95%CI 0.83-1.16;P=0.818)。
- 两组心血管死亡无统计学差异(RR 0.99;95%CI 0.73-1.333;P=0.946)。
- 两项真实世界研究比较DOAC与华法林,显示DOAC组主要心血管事件率降低。
关键数值与推荐
- 再干预率:非DOAC使用者 vs DOAC使用者,RR 1.12(95%CI 1.01-1.24;P=0.025)。
- 大出血:RR 0.78(95%CI 0.50-1.23;P=0.285)。
- 全因死亡:RR 0.98(95%CI 0.83-1.16;P=0.818)。
- 心血管死亡:RR 0.99(95%CI 0.73-1.333;P=0.946)。
临床怎么用
- 对于PAD患者,DOAC单用或联合抗血小板药可考虑作为抗栓策略,可能降低再干预率且不增加大出血风险。
- 但需注意本研究未显示DOAC在全因死亡和心血管死亡方面的获益,个体化决策仍需结合患者情况。
局限性
- 研究未能检测DOAC使用者与非使用者在全因死亡、MACEs和MALEs方面的差异。
- 未来需要更多研究以更好确定DOAC在PAD患者中的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PAD is a significant cause of morbidity and mortality affecting over 200 million people worldwide. Current guidelines recommend at least a single antiplatelet or anticoagulant agent in symptomatic PAD and lifelong antithrombotic treatment after a revascularization procedure. The aim of this systematic review and meta-analysis was to investigate the efficacy and safety of direct oral anticoagulants (DOACs) in patients with peripheral artery disease (PAD). PAD is a significant cause of morbidity and mortality affecting over 200 million people worldwide. METHODS: The present systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Risk ratios (RR) were calculated using the random effects model. RESULTS: Overall, 10 studies were included in this systematic review and meta-analysis. In 4 studies, 14,257 patients with PAD were enrolled and they were assigned to receive either aspirin (ASA)+/- clopidogrel (N = 5,894) or DOAC+/- anti-platelet (e.g., ASA, clopidogrel) (n = 8,363). Non DOAC users were found to have higher reintervention rates (RR 1.12; 95% CI 1.01-1.24; P = 0.025) compared to DOAC users. No statistically significant difference was observed between the 2 groups, in terms of major bleeding (RR 0.78; 95% CI 0.50-1.23; P = 0.285), all-cause mortality (RR 0.98; 95% CI: 0.83-1.16; P = 0.818) and cardiovascular mortality (RR: 0.99; 95% CI: 0.73-1.333; P = 0.946) mortality. In addition, two real-world studies comparing DOAC with warfarin showed decreased rates of major cardiovascular events in the DOAC group. CONCLUSION: DOAC use alone or combined with an anti-platelet agent could be associated with lower re-intervention rates, without increasing the risk for adverse bleeding events. However, this study failed to detect any difference in terms of all-cause mortality, MACEs and MALEs between DOAC users and DOAC naïve patients. Future studies are needed to better determine the efficacy and safety of DOACs in patients with PAD.
引用
- Peppas S, Sagris M, Bikakis I, et al. A Systematic Review and Meta-Analysis on the Efficacy and Safety of Direct Oral Anticoagulants in Patients with Peripheral Artery Disease. Ann Vasc Surg. 2021. PMID: 34644644. doi:10.1016/j.avsg.2021.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。